Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

about

Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.

P2860

Q48254543-2D4690AD-C305-4752-9BF6-AC3532079E91

P2860

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

Item

http://www.wikidata.org/entity/Q40459537

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Contrasting acute and chronic ...... molality in the EVEREST trial.

@en

type

Item

label

Contrasting acute and chronic ...... molality in the EVEREST trial.

@en

prefLabel

Contrasting acute and chronic ...... molality in the EVEREST trial.

@en

P1476

Contrasting acute and chronic ...... molality in the EVEREST trial.

@en

P2093

Muthiah Vaduganathan

http://www.w3.org/2001/XMLSchema#string

Steven R Goldsmith

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines

Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap

Vasopressin V1a receptor is required for nucleocytoplasmic transport of mineralocorticoid receptor

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Increased vasopressin 1A receptor expression in failing human hearts.

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis

Decongestion in acute heart failure.

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.

P304

185-191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EJHF.415

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michele Senni

Mihai Gheorghiade

Javed Butler

P577

2015-10-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26443242

http://www.w3.org/2001/XMLSchema#string

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

about

P2860

P2860

Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698